Skip to main content
EJNMMI Research
Figure 4 | EJNMMI Research

Figure 4

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Figure 4

Summary of the time course study of serial [18F] FDG-PET imaging. (a) Representative one-mouse follow-up [18F] FDG-PET images, performed at day 0 (baseline), 2 h, days 1, 3, and 9 after treatment with RO4987655, 2.5 mg/kg Tumor locations are indicated with the white circle. (b) Corresponding transverse sections through a plane of the mouse body that includes tumor (T); PM, paraspinal muscle. (c) Comparison of RO4987655, 2.5 mg/kg anti-tumor activities, and FDG-PET imaging results in NCI-H2122 tumor xenografted mice on day 0, after 2 h and days 1, 3, and 9 of the treatment (*p < 0.05, compared to baseline, day 0). The same color scale was applied to all FDG-PET images after correction for injected dose per gram tissue,% ID/gr, to show the relative [18F] FDG uptake in the tissues.

Back to article page